<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526538</url>
  </required_header>
  <id_info>
    <org_study_id>R21DA029823</org_study_id>
    <nct_id>NCT01526538</nct_id>
  </id_info>
  <brief_title>Improving Learning-based Treatment of Cocaine Dependence With Medication</brief_title>
  <official_title>Improving Learning-based Treatment of Cocaine Dependence With Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the efficacy of d-cycloserine in enhancing response to learning-based
      treatment for cocaine dependence, specifically contingency management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine dependence is a public health problem with substantial morbidity, however no
      effective pharmacotherapy for cocaine dependence has been approved by the FDA. Unlike
      previous medication studies that have sought to pharmacologically reduce cocaine
      reinforcement, seeking or craving, this exploratory clinical trial will test d-cycloserine
      (DCS) for its ability to improve learning-based behavioral treatment of cocaine dependence.
      DCS is an NMDA partial agonist that has been shown to robustly improve learning in
      preclinical models, including extinction of cocaine conditioned place preference and blockade
      of cocaine reacquisition, and to improve extinction-learning based exposure therapy for
      multiple anxiety disorders. This Phase II clinical trial will investigate the pharmacological
      (DCS) enhancement of a behavioral treatment combining contingency management (CM) and novel
      home-environment exposure therapy sessions for cocaine dependence. High magnitude CM
      incentives will be used to promote the cocaine abstinence necessary for extinction in
      home-based exposure sessions. Participants will be randomized into 2 groups: 1. CM with
      placebo (CM+PL), and 2. CM with DCS (CM+DCS). For 19 days after group assignment,
      participants will report to the laboratory 3 times per week (Mon, Wed, Fri) to provide urine
      samples, receive contingent vouchers, and complete assessments of drug use, craving, mood,
      withdrawal, and quit self-efficacy. DCS (50 mg) or placebo will be administered on Mon, Wed
      and Fri study visits (at the end of the lab visit before returning to the home environment
      for exposure sessions during the time of DCS action). Follow-up visits will be conducted at 1
      week, 1 month, and 3 months post-CM completion, during which time measures of drug use
      (self-reported and urinalysis), craving, mood, and withdrawal will be obtained. Comparison of
      continuous abstinence post-CM between the groups will be the primary outcome measure. During
      an initial laboratory session, a battery of learning/cognitive tasks will test for forms of
      learning/cognition enhanced by DCS that might contribute to the treatment effect. This
      project will test the efficacy of a novel intervention for cocaine dependence that was
      developed based on a known efficacious cocaine dependence treatment (CM), principles of
      extinction learning theory, and a medication shown to improve preclinical learning in
      general, including extinction of cocaine conditioning, and clinical learning-based exposure
      treatment of anxiety disorders. The study may indicate cost effective additions (home
      exposure sessions and DCS) to extend CM benefit after the removal of contingencies, and
      therefore may increase the dissemination of CM in community settings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)</measure>
    <time_frame>1 month post-treatment</time_frame>
    <description>The primary outcome for this study will be post-treatment continuous abstinence, as assessed by urinalysis results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication Side-effects</measure>
    <time_frame>1 month post-treatment.</time_frame>
    <description>self-report of medication side effects (Units of Measure is the count of specific reported effects)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Learning Task by Itami and Uno</measure>
    <time_frame>At the baseline laboratory visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>COCAINE-RELATED DISORDERS</condition>
  <arm_group>
    <arm_group_label>50 mg d-cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active drug condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-cycloserine</intervention_name>
    <description>50 mg d-cycloserine</description>
    <arm_group_label>50 mg d-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>placebo</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-60 years of age (&gt; 60 due to age-related effects on cognitive functioning)

          -  Satisfy DSM-IV criteria for cocaine dependence (primarily crack)

          -  Able to complete all study measures

          -  Currently seeking treatment for cocaine dependence

        Exclusion Criteria:

          -  Meets DSM-IV criteria for dependence on a drug other than cocaine or nicotine (may
             meet abuse criteria for other drugs)

          -  Pregnant, breast feeding, or planning to become pregnant within 3 months

          -  If female, do not agree to use an effective means of birth control during the course
             of treatment (via phone screen)

          -  History of seizure disorder, severe hepatic impairment, porphyria, serious head
             trauma, dementia, or significant cognitive impairment

          -  Diagnosis of current major psychiatric disorder besides substance dependence or abuse

          -  Reported use of DCS in the past year

          -  Illiteracy, as will be determined during in-person screening

          -  Concurrently prescribed or using ethionamide or isoniazid (both used to treat
             tuberculosis)

          -  Positive urine result for opioids at screening interview
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Matthew Johnson</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 mg D-cycloserine</title>
          <description>active drug condition
d-cycloserine: 50 mg d-cycloserine</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Inactive placebo
sugar pill: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50 mg D-cycloserine</title>
          <description>active drug condition
d-cycloserine: 50 mg d-cycloserine</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Inactive placebo
sugar pill: placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="5.3"/>
                    <measurement group_id="B2" value="52.1" spread="4.9"/>
                    <measurement group_id="B3" value="51.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)</title>
        <description>The primary outcome for this study will be post-treatment continuous abstinence, as assessed by urinalysis results</description>
        <time_frame>1 month post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 mg D-cycloserine</title>
            <description>active drug condition
d-cycloserine: 50 mg d-cycloserine</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Inactive placebo
sugar pill: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml)</title>
          <description>The primary outcome for this study will be post-treatment continuous abstinence, as assessed by urinalysis results</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="7.7"/>
                    <measurement group_id="O2" value="32.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Medication Side-effects</title>
        <description>self-report of medication side effects (Units of Measure is the count of specific reported effects)</description>
        <time_frame>1 month post-treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>Study medication under investigation</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo (sugar pill)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Side-effects</title>
          <description>self-report of medication side effects (Units of Measure is the count of specific reported effects)</description>
          <units>Adverse event reports</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Learning Task by Itami and Uno</title>
        <time_frame>At the baseline laboratory visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 mg D-cycloserine</title>
            <description>active drug condition
d-cycloserine: 50 mg d-cycloserine</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Inactive placebo
sugar pill: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Learning Task by Itami and Uno</title>
          <units>% correct</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" spread="3.5"/>
                    <measurement group_id="O2" value="72.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50 mg D-cycloserine</title>
          <description>active drug condition
d-cycloserine: 50 mg d-cycloserine</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Inactive placebo
sugar pill: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Johnson Ph.D.</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4105500056</phone>
      <email>mwj@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

